Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Gamma-aminobutyric acid type A (GABA_A) receptor alpha-1 beta-2 gamma-2 benzodiazepine site is a specific regulatory domain located at the interface of the α1 and γ2 subunits within the pentameric GABA_A receptor complex (Sigel & Steinmann, 2012, Journal of Biological Chemistry). This subtype, frequently termed the BZ1 or ω1 site, is the most prevalent GABA_A receptor isoform in the central nervous system and is primarily responsible for mediating the sedative, hypnotic, and anticonvulsant properties of benzodiazepine-class drugs (StatPearls, 2023, Benzodiazepines). Binding of positive allosteric modulators to this site enhances the affinity of the receptor for GABA, increasing the frequency of chloride channel opening and resulting in neuronal hyperpolarization (PubMed, PMID: 22302994). Clinically, this site is a major therapeutic target for treating sleep disorders, acute anxiety, and seizure activity (PubChem, CID 46173048). However, long-term modulation of this receptor can lead to significant clinical challenges, including the development of tolerance, dependence, and potential for abuse (NIH, National Institute on Drug Abuse). Selective ligands for the α1 subunit, such as zolpidem, are utilized to provide targeted hypnotic effects while minimizing the muscle-relaxant and anxiolytic effects associated with other GABA_A subtypes (Wikipedia, GABA_A receptor). The site is also the target for the antagonist flumazenil, which is used to reverse benzodiazepine overdose by competitively displacing agonists from the binding pocket (StatPearls, 2023, Flumazenil). Understanding the specific subunit composition of this receptor is crucial for developing next-generation neuro-psychiatric medications with improved safety profiles (UniProt, P14867).
Positive allosteric modulation of GABA-induced chloride currents; competitive antagonism; inverse agonism
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid type A receptor (GABA_A receptor) alpha-1 beta-2 gamma-2 benzodiazepine site (GABA_A receptor α1βγ2 BZ site).